… to review all possible immunotherapies that failed during past and present years, we have
chosen to focus our analysis here only on FDA-approved cancer immunotherapies that have …

… from multiple cancer models have provided sufficient evidence to propose a paradigm shift,
… by adding radiotherapy to immunotherapy in metastatic cancer patients support this view. …

… Despite the initial limited efficacy of immunotherapy in treatment of … interest as a potential
treatment paradigm, particularly in light of … Checkpoint blockade in cancer immunotherapy …

… This may be true for the prior failures and risks of novel cancer immunotherapies. We also
… cancer immunotherapies. Here we present several case studies in cancer immunotherapy …

… cancers for which there have been few treatment options. This article discusses the history of
cancer immunotherapy … of caution on limitations of immunotherapies, their potential harms, …

… in hormone-positive breast cancer (30% vs 13%) and triple-negative breast cancer (60% vs
22%… In bladder cancer, 2 neoadjuvant phase II trials using atezolizumab and pembrolizumab …

… the growth of cancer cells. Sipuleucel-T is approved by the FDA as an immunotherapeutic
agent for … or minimally symptomatic castration-resistant prostate cancer (CRPC). Although this …

… chemotherapeutic drugs directly to cancer cells (Table 1). Here, we aim to contribute to a
paradigm shift in which nanoparticles (… Enhancing cancer immunotherapy with nanomedicine …

… mergence of immunotherapeutic strategies of cancer treatment has opened a new direction …
Immunotherapy harnesses patients own immune system to eradicate cancer cells further to …

… development of various strategies of cancer immunotherapy, relying on the … immunotherapy
because they provided directly to the patient the immune effectors needed to fight his cancer …